Your browser is no longer supported. Please, upgrade your browser.
BPMC Blueprint Medicines Corporation daily Stock Chart
BPMC [NASD]
Blueprint Medicines Corporation
Index- P/E- EPS (ttm)-7.66 Insider Own1.10% Shs Outstand54.22M Perf Week2.25%
Market Cap5.55B Forward P/E- EPS next Y-7.31 Insider Trans-22.86% Shs Float53.91M Perf Month32.72%
Income-395.00M PEG- EPS next Q7.66 Inst Own97.90% Short Float7.81% Perf Quarter30.62%
Sales75.20M P/S73.84 EPS this Y-34.80% Inst Trans0.34% Short Ratio9.94 Perf Half Y46.07%
Book/sh10.72 P/B9.56 EPS next Y-537.70% ROA-49.70% Target Price102.57 Perf Year30.24%
Cash/sh9.63 P/C10.64 EPS next 5Y22.27% ROE-70.40% 52W Range43.29 - 105.49 Perf YTD27.91%
Dividend- P/FCF- EPS past 5Y-32.50% ROI-77.80% 52W High-2.86% Beta0.98
Dividend %- Quick Ratio5.40 Sales past 5Y- Gross Margin99.80% 52W Low136.71% ATR3.48
Employees419 Current Ratio5.40 Sales Q/Q62.70% Oper. Margin- RSI (14)72.61 Volatility3.81% 3.39%
OptionableYes Debt/Eq0.00 EPS Q/Q-11.60% Profit Margin- Rel Volume1.22 Prev Close103.89
ShortableYes LT Debt/Eq0.00 EarningsJul 30 BMO Payout- Avg Volume423.38K Price102.47
Recom1.70 SMA207.28% SMA5023.74% SMA20043.31% Volume514,493 Change-1.37%
Jul-15-20Reiterated H.C. Wainwright Buy $66 → $110
May-05-20Initiated Barclays Equal Weight $59
Mar-17-20Upgrade BMO Capital Markets Market Perform → Outperform $74 → $89
Jan-28-20Initiated BMO Capital Markets Market Perform
Jan-27-20Initiated BMO Capital Markets Market Perform
Nov-06-19Upgrade Raymond James Outperform → Strong Buy $106 → $112
Oct-22-19Initiated JMP Securities Mkt Outperform $106
Oct-03-19Initiated H.C. Wainwright Buy $100
Sep-12-19Upgrade Raymond James Mkt Perform → Outperform
Aug-29-19Initiated Piper Jaffray Neutral $85
Aug-15-19Resumed Raymond James Mkt Perform
Jul-18-19Initiated Deutsche Bank Buy $110
May-23-19Resumed Goldman Buy $125
Apr-03-19Initiated Morgan Stanley Overweight $112
Sep-25-18Initiated Leerink Partners Outperform
Dec-11-17Reiterated Goldman Buy $82 → $99
Sep-29-17Initiated BTIG Research Buy $90
Apr-05-17Reiterated Wedbush Outperform $43 → $50
Mar-13-17Upgrade Goldman Neutral → Buy
Feb-15-17Initiated Morgan Stanley Overweight
Oct-02-20 04:01PM  
Sep-30-20 07:17AM  
Sep-29-20 11:46AM  
Sep-28-20 12:38PM  
Sep-25-20 11:46AM  
Sep-23-20 12:54PM  
09:30AM  
08:05AM  
Sep-22-20 04:23PM  
07:00AM  
Sep-20-20 08:25AM  
Sep-17-20 08:00AM  
Sep-13-20 07:27AM  
Sep-09-20 08:29PM  
04:01PM  
Sep-04-20 07:00PM  
08:00AM  
Sep-01-20 08:00AM  
Aug-29-20 11:31AM  
Aug-04-20 08:00AM  
Aug-01-20 08:21AM  
Jul-31-20 11:18AM  
Jul-30-20 08:35AM  
07:28AM  
07:00AM  
Jul-24-20 08:30AM  
Jul-23-20 08:00AM  
Jul-14-20 05:22PM  
12:23PM  
12:22PM  
08:28AM  
08:04AM  
06:23AM  
03:56AM  
01:00AM  
Jul-13-20 08:25PM  
Jul-02-20 04:01PM  
12:25PM  
Jul-01-20 08:00AM  
Jun-29-20 06:30PM  
Jun-06-20 09:00AM  
Jun-05-20 11:32AM  
Jun-03-20 08:00AM  
07:11AM  
03:05AM  
May-29-20 01:13PM  
08:00AM  
May-27-20 04:30PM  
May-26-20 08:00AM  
May-18-20 12:16PM  
May-15-20 12:10PM  
08:00AM  
May-14-20 11:29PM  
12:00PM  
09:00AM  
May-12-20 11:36AM  
May-07-20 12:58PM  
08:01AM  
May-06-20 08:35AM  
07:00AM  
Apr-28-20 11:19AM  
10:27AM  
07:00AM  
Apr-16-20 06:30AM  
Apr-09-20 12:00PM  
Apr-01-20 08:00AM  
Mar-27-20 03:51PM  
Mar-16-20 07:00AM  
Mar-14-20 11:30AM  
Mar-09-20 09:00AM  
Mar-06-20 06:10AM  
Feb-20-20 03:45AM  
Feb-19-20 06:16PM  
08:00AM  
Feb-18-20 12:52PM  
Feb-14-20 10:42AM  
Feb-13-20 10:31AM  
08:25AM  
Feb-07-20 11:21AM  
07:32AM  
Feb-06-20 08:00AM  
Feb-03-20 11:27AM  
Jan-30-20 11:04AM  
Jan-22-20 10:24PM  
08:25AM  
Jan-21-20 04:01PM  
Jan-16-20 04:59AM  
Jan-13-20 08:00AM  
Jan-12-20 12:19PM  
Jan-11-20 06:45PM  
Jan-10-20 10:27AM  
08:49AM  
Jan-09-20 05:16PM  
03:52PM  
10:31AM  
Jan-08-20 08:00AM  
Jan-07-20 10:26AM  
Jan-06-20 08:00AM  
Dec-13-19 09:25AM  
Dec-12-19 09:56AM  
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in genomically defined cancers, rare diseases, and cancer immunotherapy. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase I clinical trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib, an orally available and potent inhibitor that targets RET, a receptor tyrosine kinase for the treatment of RET-altered non-small cell lung cancer, medullary thyroid carcinoma, and other solid tumors. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Haviland KateChief Operating OfficerOct 16Option Exercise36.0513,334480,69156,172Oct 20 04:09 PM
Haviland KateChief Operating OfficerOct 16Sale101.2313,3341,349,84842,838Oct 20 04:09 PM
Goldberg Mark AlanDirectorOct 07Option Exercise19.535,454106,5179,016Oct 09 04:04 PM
Albers Jeffrey W.CEO and PresidentOct 07Option Exercise8.805,00044,000146,434Oct 09 04:05 PM
Hurley ArielPrincipal Accounting OfficerOct 07Option Exercise8.806005,28010,584Oct 09 04:06 PM
Albers Jeffrey W.CEO and PresidentOct 07Sale99.175,000495,850141,434Oct 09 04:05 PM
Goldberg Mark AlanDirectorOct 07Sale100.005,454545,4003,562Oct 09 04:04 PM
Hurley ArielPrincipal Accounting OfficerOct 07Sale100.0060060,0009,984Oct 09 04:06 PM
Dorsch MarionChief Scientific OfficerOct 06Option Exercise37.114,600170,70619,850Oct 08 04:16 PM
Dorsch MarionChief Scientific OfficerOct 06Sale99.004,600455,40015,250Oct 08 04:16 PM
Lydon NicholasDirectorOct 01Sale93.089,815913,59537,425Oct 05 04:17 PM
Durso-Bumpus DebraChief People OfficerSep 23Option Exercise36.051,90068,49521,405Sep 25 04:26 PM
Dorsch MarionChief Scientific OfficerSep 23Option Exercise37.114,600170,70619,850Sep 25 04:27 PM
Hurley ArielPrincipal Accounting OfficerSep 23Option Exercise1.871,4002,61811,384Sep 25 04:27 PM
Hurley ArielPrincipal Accounting OfficerSep 23Sale90.001,400126,0009,984Sep 25 04:27 PM
Dorsch MarionChief Scientific OfficerSep 23Sale89.004,600409,40015,250Sep 25 04:27 PM
Durso-Bumpus DebraChief People OfficerSep 23Sale90.021,900171,03819,505Sep 25 04:26 PM
Haviland KateChief Operating OfficerSep 22Option Exercise16.283,14351,16845,981Sep 24 04:19 PM
Boral Anthony L.Chief Medical OfficerSep 22Option Exercise15.016,864103,02925,828Sep 24 04:22 PM
Demetri GeorgeDirectorSep 22Sale85.001,704144,8404,320Sep 24 04:22 PM
Boral Anthony L.Chief Medical OfficerSep 22Sale82.336,864565,11318,964Sep 24 04:22 PM
Haviland KateChief Operating OfficerSep 22Sale85.493,143268,69542,838Sep 24 04:19 PM
Boral Anthony L.Chief Medical OfficerSep 17Option Exercise11.4523,136264,94542,100Sep 21 04:22 PM
Lydon NicholasDirectorSep 17Sale80.0050040,00047,240Sep 21 04:21 PM
Boral Anthony L.Chief Medical OfficerSep 17Sale80.0023,1361,850,88018,964Sep 21 04:22 PM
Albers Jeffrey W.CEO and PresidentAug 19Option Exercise8.8020,000176,000161,434Aug 21 04:22 PM
Albers Jeffrey W.CEO and PresidentAug 19Sale75.0220,0001,500,438141,434Aug 21 04:22 PM
Hurley ArielPrincipal Accounting OfficerAug 17Option Exercise1.877001,30910,684Aug 19 04:52 PM
Hurley ArielPrincipal Accounting OfficerAug 17Sale75.0070052,5009,984Aug 19 04:52 PM
Lydon NicholasDirectorJul 06Sale80.4526,0072,092,35147,740Jul 08 04:25 PM
Lydon NicholasDirectorJul 02Sale80.132,825226,36773,747Jul 06 06:30 PM
Lydon NicholasDirectorJul 01Sale80.211,300104,27376,572Jul 06 06:30 PM
Lydon NicholasDirectorJun 23Sale80.0040032,00075,622Jun 25 04:10 PM
Durso-Bumpus DebraChief People OfficerJun 22Option Exercise36.052,30082,91521,805Jun 24 04:14 PM
Durso-Bumpus DebraChief People OfficerJun 22Sale80.072,300184,16119,505Jun 24 04:14 PM
Lydon NicholasDirectorJun 22Sale80.2913,0171,045,13576,022Jun 23 04:13 PM
Dorsch MarionChief Scientific OfficerJun 19Option Exercise37.114,600170,70619,850Jun 23 04:10 PM
Dorsch MarionChief Scientific OfficerJun 19Sale79.004,600363,40015,250Jun 23 04:10 PM
Durso-Bumpus DebraChief People OfficerJun 18Option Exercise18.002,50045,00022,005Jun 22 04:21 PM
Durso-Bumpus DebraChief People OfficerJun 18Sale75.182,500187,95019,505Jun 22 04:21 PM
Hurley ArielPrincipal Accounting OfficerJun 09Option Exercise1.877001,30910,684Jun 11 05:20 PM
Hurley ArielPrincipal Accounting OfficerJun 09Sale75.0070052,5009,984Jun 11 05:20 PM
Hurley ArielPrincipal Accounting OfficerJun 02Sale66.0323515,5179,984Jun 04 04:37 PM
Albers Jeffrey W.CEO and PresidentMay 12Option Exercise8.8020,000176,000161,434May 14 04:38 PM
Albers Jeffrey W.CEO and PresidentMay 12Sale64.6720,0001,293,427141,434May 14 04:38 PM
Albers Jeffrey W.CEO and PresidentMar 23Option Exercise5.3240,000212,846161,434Mar 25 04:22 PM
Dorsch MarionChief Scientific OfficerMar 23Sale52.491,21463,72615,250Mar 25 04:22 PM
Albers Jeffrey W.CEO and PresidentMar 23Sale52.1020,0001,041,922141,434Mar 25 04:22 PM
Hurley ArielPrincipal Accounting OfficerMar 09Sale51.9425313,1419,984Mar 11 04:32 PM
Boral Anthony L.Chief Medical OfficerMar 09Sale51.9753627,85618,964Mar 11 04:31 PM
Albers Jeffrey W.CEO and PresidentMar 09Sale51.972,277118,336121,434Mar 11 04:31 PM
Durso-Bumpus DebraChief People OfficerMar 09Sale51.9443222,43819,505Mar 11 04:30 PM
Dorsch MarionChief Scientific OfficerMar 09Sale51.9953627,86716,464Mar 11 04:30 PM
Landsittel MichaelChief Financial OfficerMar 09Sale51.9740020,78817,350Mar 11 04:29 PM
Haviland KateChief Operating OfficerMar 09Sale51.9867134,87942,838Mar 11 04:29 PM
Rossi ChristinaChief Commercial OfficerMar 09Sale51.961357,01520,365Mar 11 04:27 PM
Murray Christopher K.SVP, Technical OperationsMar 09Sale51.9440220,88013,848Mar 11 04:28 PM
McCain Tracey LEVP and Chief Legal OfficerMar 09Sale51.9861732,07221,683Mar 11 04:28 PM
Haviland KateChief Operating OfficerMar 03Option Exercise16.284,64475,60443,509Mar 03 07:12 PM
Haviland KateChief Operating OfficerJan 10Option Exercise16.287,763126,38223,628Jan 14 04:47 PM
Demetri GeorgeDirectorJan 10Sale85.0056848,2802,462Jan 14 04:48 PM
Haviland KateChief Operating OfficerJan 10Sale85.167,763661,09715,865Jan 14 04:47 PM
Demetri GeorgeDirectorJan 07Sale80.591,705137,4063,030Jan 09 04:10 PM
Dorsch MarionChief Scientific OfficerDec 19Option Exercise37.114,600170,7064,600Dec 23 05:32 PM
Dorsch MarionChief Scientific OfficerDec 19Sale79.004,600363,4000Dec 23 05:32 PM
Boral Anthony L.Chief Medical OfficerDec 17Option Exercise8.8010,00088,00010,000Dec 19 04:38 PM
Boral Anthony L.Chief Medical OfficerDec 17Sale76.5710,000765,7130Dec 19 04:38 PM
Hurley ArielPrincipal Accounting OfficerDec 16Option Exercise1.87415776415Dec 18 04:33 PM
Hurley ArielPrincipal Accounting OfficerDec 16Sale75.0041531,1250Dec 18 04:33 PM
Hurley ArielPrincipal Accounting OfficerDec 04Sale77.2519214,8320Dec 06 04:32 PM
Albers Jeffrey W.CEO and PresidentNov 18Option Exercise2.5620,00051,26068,961Nov 20 05:07 PM
Albers Jeffrey W.CEO and PresidentNov 18Sale75.428,256622,65260,705Nov 20 05:07 PM
Hurley ArielPrincipal Accounting OfficerNov 15Option Exercise1.87415776415Nov 19 04:16 PM
Hurley ArielPrincipal Accounting OfficerNov 15Sale75.0041531,1250Nov 19 04:16 PM
Albers Jeffrey W.CEO and PresidentNov 08Sale74.5611,744875,63348,961Nov 20 05:07 PM
Albers Jeffrey W.CEO and PresidentOct 30Option Exercise1.8720,00037,40048,961Oct 30 04:32 PM